DAFNA Capital Management LLC Sells 122,840 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)

DAFNA Capital Management LLC cut its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 24.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 371,434 shares of the company's stock after selling 122,840 shares during the period. DAFNA Capital Management LLC owned 0.58% of Larimar Therapeutics worth $1,437,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of LRMR. BNP Paribas Financial Markets acquired a new position in Larimar Therapeutics in the fourth quarter valued at approximately $25,000. Algert Global LLC acquired a new position in Larimar Therapeutics in the fourth quarter valued at approximately $47,000. China Universal Asset Management Co. Ltd. bought a new stake in Larimar Therapeutics in the fourth quarter valued at approximately $52,000. Aquatic Capital Management LLC acquired a new position in shares of Larimar Therapeutics in the 4th quarter valued at $70,000. Finally, Virtu Financial LLC acquired a new position in shares of Larimar Therapeutics in the 3rd quarter valued at $71,000. Institutional investors own 91.92% of the company's stock.

Larimar Therapeutics Stock Performance

LRMR traded down $0.22 on Tuesday, reaching $1.86. The company had a trading volume of 912,122 shares, compared to its average volume of 876,276. The business has a 50 day simple moving average of $2.28 and a 200 day simple moving average of $3.98. The company has a market cap of $119.09 million, a price-to-earnings ratio of -1.62 and a beta of 0.93. Larimar Therapeutics, Inc. has a 52-week low of $1.61 and a 52-week high of $11.20.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04). As a group, equities research analysts predict that Larimar Therapeutics, Inc. will post -1.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on LRMR. Truist Financial started coverage on shares of Larimar Therapeutics in a research report on Wednesday, January 29th. They set a "buy" rating and a $18.00 price objective for the company. Guggenheim restated a "buy" rating and set a $26.00 target price on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. HC Wainwright raised their target price on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the company a "buy" rating in a report on Tuesday, March 25th. Citigroup reaffirmed a "buy" rating on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Finally, Robert W. Baird reduced their target price on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating on the stock in a report on Tuesday, March 25th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $19.63.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.